- UK research linked semaglutide with nearly 40% fewer asthma attacks and around 20% fewer COPD flare-ups.
- The findings came from medical records, not a trial randomly assigning people to treatment.
- Researchers say the results should not prompt people to start GLP-1 medicines specifically for a lung condition.
Semaglutide may have a benefit beyond blood glucose and weight: fewer serious flare-ups of existing lung disease.
Research presented at the European Respiratory Society Congress linked its use with nearly 40% fewer asthma attacks and around 20% fewer exacerbations of chronic obstructive pulmonary disease, or COPD.
The Imperial College London team examined UK health records in four parallel studies, each involving roughly 20,000 to 22,000 people.
They compared people starting GLP-1 medicines with those starting sulfonylureas, another class of diabetes treatment.
Semaglutide showed the strongest association with fewer respiratory attacks.
The comparison is important. This was not a test of semaglutide against an asthma inhaler, and it did not establish that the medicine could replace respiratory treatment.
Nor were participants randomly assigned to the diabetes medicines.
People prescribed different treatments may differ in ways that medical records cannot fully capture, making it difficult to separate the drug’s effect from other influences.
For someone already managing diabetes alongside asthma or COPD, the possibility of an additional respiratory benefit is nevertheless worth investigating.
The researchers suggest anti-inflammatory effects may be involved, but the findings do not establish the mechanism.
Further trials would need to measure lung function, symptoms and attacks directly.
That leaves an important gap between an encouraging association and a treatment recommendation.
- Orforglipron pill beats oral semaglutide in major diabetes trial
- Tirzepatide and semaglutide reduce heart attack, stroke and death risk
- Dementia risk reduced by using semaglutide, study reveals
A medicine can look promising in routine records without yet having the evidence needed to prescribe it for a different condition.
Existing inhaler treatment still has a clear purpose.
Preventer medicines reduce airway inflammation, while appropriate reliever treatment helps manage symptoms when they occur.
Their use should follow the person’s prescribed treatment plan.
Improved breathing after starting a diabetes medicine would therefore be something to discuss at a review, not a reason to quietly stop an inhaler.
For now, this research provides a reason to study respiratory outcomes in GLP-1 trials, rather than a reason to change asthma care ahead of the evidence.
